Characterization of Abdomino-pelvic Lesions by 18Fluorine- Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: PET/CT.
- Who it may be relevant to
- Registry conditions: Abdominal Sepsis. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Characterization of Abdomino-pelvic Lesions in Cancer Patients by 18F-FDG PET/CT
Overview
The aim of the study is to identify and characterize lesions in the abdominopelvic region detected by 18fluorine- fluorodeoxyglucose (FDG) positron Emission Tomography combined Computed Tomography (PET/CT) scan, including determining their malignant or benign nature, and to determine the extent of disease to facilitate proper management
Detailed description
positron Emission Tomography combined Computed Tomography is a hybrid imaging that provides both anatomical and functional data that helps to differentiate between benign and malignant diseases. \[18F\]FDG is taken up by both normal cells utilizing glucose like (kidneys, ureters and urinary bladder due to urinary excretion, Variable degrees of uptake can also seen in the liver, spleen, bone marrow, bowel, testes and uterus) .and also the tumor cells which usually have a high glucose demand. This uptake is mediated by the cell surface carrier molecules designated as glucose transporters (GLUT) and can be measured with the semi quantitative index called standardized uptake values (SUV) Cancer cells divide rapidly and have greater metabolic rates. Through the upregulation of glucose transport proteins on the cell membrane, cancer cells exhibit enhanced glucose uptake . Studies have demonstrated that SUV of 2.5 can differentiate malignant versus benign tissues , thus, Proper characterization of abdomino-pelvic lesions will lead to improve chances for successful management and treatment.
Multiple studies have shown that Dual-time point (DTP) 18F-FDG PET/CT may provide more help in the differentiation of malignant lesions from benign ones.as Dual-Time-Point PET/CT involves two scans, one early and one delayed, allowing for the assessment of FDG uptake kinetics, malignant tumors tend to show increased FDG uptake over time, indicating higher glucose metabolism. But benign Lesions or those with inflammatory processes may show a decrease or no significant change in FDG uptake over time.
FDG activity in urine interferes with tumor activity. Therefore, the value of FDG PET has only a limited role in detecting tumors in the bladder wall and urinary tract, Thus several methods have been investigated and tested to reduce urine FDG activity: catheterization, dual-phase imaging, early PET images, late PET images after voiding, oral hydration, and forced diuresis
Interventions
- Device PET/CT
positron emission tomography/computed tomography
Primary outcome measures
- Evaluate the performance of 18F FDG PET/CT [Time frame: 3 years]
Secondary outcome measures (1)
- Evaluate the diagnostic power of alternative technologies [Time frame: 3 years]
Eligibility criteria
Inclusion criteria
- Inclusion criteria: All of the patients were suspected of having malignancy (new, recurrent or metastatic) based on pathology or conventional radiological studies and were referred to nuclear medicine unit for 18F-FDG-PET-CT scan
Exclusion criteria
- patients underwent recent abdominal or pelvic surgery.
- patients with blood glucose level ˃200 mg/dL
- Pregnancy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Bouchelouche K. PET/CT in Bladder Cancer: An Update. Semin Nucl Med. 2022 Jul;52(4):475-485. doi: 10.1053/j.semnuclmed.2021.12.004. Epub 2022 Jan 5. PMID 34996595
- Khandelwal Y, Singh Parihar A, Sistani G, Ramirez-Fort MK, Zukotynski K, Subramaniam RM. Role of PET/Computed Tomography in Gastric and Colorectal Malignancies. PET Clin. 2024 Apr;19(2):177-186. doi: 10.1016/j.cpet.2023.12.004. Epub 2024 Jan 9. PMID 38199915
- Wang J, Liu X. Medical image recognition and segmentation of pathological slices of gastric cancer based on Deeplab v3+ neural network. Comput Methods Programs Biomed. 2021 Aug;207:106210. doi: 10.1016/j.cmpb.2021.106210. Epub 2021 May 29. PMID 34130088
- Sartin SL, Shetty DR, Strange CD, Gayer G, Ahuja J, Agrawal R, Truong MT. Pitfalls in Positron Emission Tomography/Computed Tomography in the Thorax and Abdomen. Semin Ultrasound CT MR. 2024 Dec;45(6):488-495. doi: 10.1053/j.sult.2024.07.012. Epub 2024 Jul 26. PMID 39069275
- Cao Y, Zhou K, Diao W, Long X, Tian F, Su M, Jia Z. Age-related changes of standardized uptake values in the blood pool and liver: a decade-long retrospective study of the outcomes of 2,526 subjects. Quant Imaging Med Surg. 2021 Jan;11(1):95-106. doi: 10.21037/qims-20-35. PMID 33392014
Identifiers
NCT: NCT07127627 · characterization by PET/CT